Sign in

    Cencora Inc (COR)

    Financials

    Updated May 7, 2025, 7:03 PM UTC
    Income Statement - MetricQ1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025Q2 2025
    Revenue (USD, thousands)262,173,41172,252,83368,414,307.0074,241,353.0079,050,106.00293,958,59981,487,06075,453,673
    Cost of goods sold (USD, thousands)253,213,91869,784,02165,876,284.0071,830,576.0076,557,689.00284,048,57078,929,02272,393,864
    Gross profit (USD, thousands)8,959,4932,468,8122,538,023.002,410,777.002,492,417.009,910,0292,558,0383,059,809
    Distribution, selling, and administrative expenses (USD, thousands)5,309,9841,398,7471,388,810.001,383,206.001,490,343.005,661,1061,472,0551,600,040
    Litigation and opioid-related expenses (credit), net (USD, thousands)(24,693)(78,917)225,985.0014,485.0065,517.00227,07016,76511,524
    Acquisition-related deal and integration expenses (USD, thousands)139,68321,06322,610.0025,758.0033,570.00103,00138,71299,380
    Restructuring and other expenses (USD, thousands)229,88434,44175,627.0042,257.0081,304.00233,62945,76052,857
    Operating income (USD, thousands)2,340,731822,875553,259.00672,476.002,175,249706,2541,036,190
    Other loss (income), net (USD, thousands)(49,036)(1,087)22,063.0012,814.00(19,507.00)14,28357,8743,546
    Interest expense, net (USD, thousands)228,93140,56464,130.0031,328.0020,969.00156,99127,933103,988
    Income before income taxes (USD, thousands)2,160,836783,398467,066.00628,334.00125,177.002,003,975620,447928,656
    Income tax expense (USD, thousands)428,260180,39045,861.00140,740.00117,711.00484,702126,728211,239
    Net income (USD, thousands)1,732,576603,008421,205.00487,594.001,519,273493,719717,417
    Net income attributable to noncontrolling interests (USD, thousands)12,717(1,508)(430.00)(4,131.00)(4,084.00)(10,153)(5,119)454
    Net income attributable to Cencora, Inc. (USD, thousands)1,745,293601,500420,775.00483,463.003,382.001,509,120488,600717,871
    Basic earnings per share (USD)8.623.012.112.447.602.523.70
    Diluted earnings per share (USD)8.532.982.092.420.047.532.503.68
    Basic weighted average common shares outstanding (thousands)202,511200,081(334.00)(494.00)(750.00)198,503193,758193,796
    Diluted weighted average common shares outstanding (thousands)204,591201,837(327.00)(485.00)(741.00)200,284195,188195,094
    Balance Sheet - MetricQ1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025Q2 2025
    Cash and cash equivalents (USD, thousands)2,592,0512,872,3513,306,2003,132,6483,132,6483,224,2601,978,061
    Accounts receivable, less allowances for returns and credit losses (USD, thousands)20,911,08121,576,59422,642,88024,051,47823,871,81523,871,81524,545,72423,715,008
    Inventories (USD, thousands)17,454,76818,652,24017,630,98518,301,54618,998,83318,998,83320,508,02018,965,502
    Right to recover assets (USD, thousands)1,314,8571,242,9781,194,9151,143,7311,175,8711,175,8711,192,7071,301,531
    Prepaid expenses and other (USD, thousands)448,949492,977512,039459,662450,417450,417515,923574,871
    Total current assets (USD, thousands)42,798,82644,858,73144,161,05247,307,26247,717,81347,717,81349,986,63446,534,973
    Property and equipment, net (USD, thousands)2,135,1712,117,2832,089,4972,080,8792,181,4102,181,4102,099,7872,302,809
    Deferred income taxes (USD, thousands)1,657,9441,690,7851,701,7351,607,6611,643,7461,643,7461,585,9361,615,752
    Other assets (USD, thousands)3,418,1823,458,9853,565,9963,530,0663,637,0233,637,0233,889,0204,168,145
    TOTAL ASSETS (USD, thousands)62,558,74664,690,29763,868,04666,772,42367,101,66767,101,66769,054,31471,193,874
    Accounts payable (USD, thousands)45,836,03747,743,47446,320,77449,883,04950,942,16250,942,16249,910,85350,110,563
    Accrued expenses and other (USD, thousands)2,353,8172,437,2192,371,8852,525,7102,758,5602,758,5602,385,0262,447,498
    Short-term debt (USD, thousands)641,344592,7791,069,152565,108576,331576,331770,321
    Total current liabilities (USD, thousands)48,831,19850,773,47249,761,81152,973,86754,277,05354,277,05354,509,10553,328,382
    Long-term debt (USD, thousands)4,146,1134,185,9444,180,3064,165,9103,811,7453,811,7457,085,886
    Accrued income taxes (USD, thousands)310,676335,293315,559332,364291,796291,796303,433277,738
    Accrued litigation liability (USD, thousands)5,061,7954,731,9454,719,5454,697,6954,296,9024,296,9024,296,9024,284,602
    Other liabilities (USD, thousands)1,884,7331,911,6021,962,0681,934,4231,993,6831,993,6832,061,7153,421,715
    Total stockholders' equity (USD, thousands)666,2871,061,2561,227,0221,060,503786,742786,7421,179,799
    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (USD, thousands)62,558,74664,690,29763,868,04666,772,42367,101,66767,101,66769,054,31471,193,874
    Cash Flow - MetricQ1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025Q2 2025
    Net income (USD, thousands)1,732,576603,008421,205.00487,594.007,466.001,519,273493,719717,417.00
    NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES (USD, thousands)3,911,334885,1571,000,379.003,484,6853,351,238.00
    Capital expenditures (USD, thousands)(458,359)(74,217)(112,753.00)(117,879.00)(182,324.00)(487,173)(105,893)(129,060.00)
    Cost of acquired companies, net of cash acquired (USD, thousands)(1,409,835)--(22,177.00)(45,284.00)(69,771)(9,015)(3,938,746.00)
    Cost of equity investments (USD, thousands)(743,275)--(6,960.00)(15,449.00)(30,430)(182,014)(10,562.00)
    Other, net (Investing Activities) (USD, thousands)9,0048,4176,597.003,092.001,172.0019,278(11,303)745.00
    NET CASH USED IN INVESTING ACTIVITIES (USD, thousands)(2,602,465)(65,800)(166,487.00)(143,924.00)(241,885.00)(618,096)(343,039)(4,077,623.00)
    Purchases of common stock (USD, thousands)(1,180,728)(385,533)(50,845.00)(550,010.00)(504,979.00)(1,491,367)(385,471)(50,000.00)
    Exercises of stock options (USD, thousands)61,15210,9267,703.0012,931.006,280.0037,8408,1087,670.00
    Cash dividends on common stock (USD, thousands)(398,752)(105,690)(107,002.00)(102,531.00)(100,945.00)(416,168)(110,888)(111,188.00)
    Employee tax withholdings related to restricted share vesting (USD, thousands)(71,279)(56,248)(3,838.00)(35.00)(3,379.00)(63,500)(73,963)(3,595.00)
    Other, net (Financing Activities) (USD, thousands)(9,413)(4,655)(5,726.00)(1,260.00)(706.00)(12,347)(16,876)(1,886.00)
    NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES (USD, thousands)(2,222,278)(551,669)323,170.00(1,145,235.00)(957,260.00)(2,330,994)3,209,150(491,738.00)
    EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH (USD, thousands)72,75915,544(29,215.00)2,817.0020,250.009,396(50,235)1,715.00
    Non-customer note receivable (USD, thousands)--(50,000)(50,000)(50,000)(50,000)(34,814)(34,814)
    Cash, cash equivalents, and restricted cash at beginning of period (USD, thousands)3,593,5392,752,8892,752,8892,752,8892,752,8892,752,8893,297,8803,297,880
    Cash, cash equivalents, and restricted cash at end of period (USD, thousands)2,752,8893,036,1212,285,1463,476,3963,297,8803,297,8803,394,9742,178,566
    Revenue by Segment - in Millions of USDQ1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025Q2 2025
    U.S. Healthcare Solutions234,759-----74,033.128-
    - Human Health229,71763,89859,984.465,821.970,269.6259,973.972,653.143-
    - Animal Health5,0431,2861,308.51,369.71,401.35,365.51,379.985-
    International Healthcare Solutions27,419-----7,457.341-
    - Alliance Healthcare22,3495,7265,755.05,641.95,938.823,061.75,999.200-
    - Other Healthcare Solutions5,0691,3451,368.41,410.01,442.45,565.81,458.141-
    Pharmaceutical Distribution Services--------
    Other Segments--------
    - MWI Animal Health--------
    - Global Commercialization Services--------
    Intersegment Eliminations-4-1-2.0-2.1-3.3-8.4(3.409)-
    Total Revenue262,17372,25368,414.374,241.479,049.9293,958.681,487.060-
    Revenue by Geography - in Millions of USDQ1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025Q2 2025
    U.S. Healthcare Solutions234,759.21865,183.861,292.967,191.671,671.13265,339.42774,033.1-
    International Healthcare Solutions27,418.6797,070.27,123.47,051.887,382.0628,627.5427,457.3-
    - Alliance Healthcare------5,999.2-
    - Other Healthcare Solutions------1,458.1-
    Intersegment Eliminations--------
    Total Revenue262,173.41172,252.868,414.374,241.3579,050.15293,958.59981,487.1-
    KPIs - Metric [Unit: Days]Q1 2014Q2 2014Q3 2014Q4 2014FY 2014Q1 2015Q2 2015Q3 2015Q4 2015FY 2015Q1 2016Q2 2016Q3 2016Q4 2016FY 2016Q1 2017Q2 2017Q3 2017Q4 2017FY 2017Q1 2018Q2 2018Q3 2018Q4 2018FY 2018Q1 2019Q2 2019Q3 2019Q4 2019FY 2019Q1 2020Q2 2020Q3 2020Q4 2020FY 2020Q1 2021Q2 2021Q3 2021Q4 2021FY 2021Q1 2022Q2 2022Q3 2022Q4 2022FY 2022Q1 2023Q2 2023Q3 2023Q4 2023FY 2023Q1 2024Q2 2024Q3 2024Q4 2024FY 2024Q1 2025Q2 2025
    Days Sales Outstanding (Days)27.728.029.629.0-28.727.8-
    Days Inventory On Hand (Days)27.726.528.025.8-26.426.0-
    Days Payable Outstanding (Days)60.059.562.460.1-60.358.5-